# 2012

Venice, Italy

I-01 Robert LearyQRPEM, A Quasi-Random Parametric EM Method Wednesday 10:15-11:45 |

I-02 Donghwan LeeQuantitative Analysis of Reflux Episodes in Gastroesophageal Reflux Disease (GERD)Wednesday 10:15-11:45 |

I-03 Eun-Kyung LeeVarious validation methods to check the estimation methods with stochastic sampling approachWednesday 10:15-11:45 |

I-04 Joomi LeePopulation Pharmacokinetics of Sumatriptan in Healthy Korean Male SubjectsWednesday 10:15-11:45 |

I-05 Annabelle Lemenuel DiotIdentification of a dual mechanism of action (MoA) for Danoprevir (DNV), a protease inhibitor currently in phase 2, using a mechanistic viral kinetic modelWednesday 10:15-11:45 |

I-06 Sergei LeonovOptimal design of population pharmacokinetic/pharmacodynamic studiesWednesday 10:15-11:45 |

I-07 Claire LiClinical trial simulations of the anticancer agents- abiraterone and nilotinibWednesday 10:15-11:45 |

I-08 Earvin LiangClinical Trial Design Optimization: A Pharmacokinetic Sampling Plan for a Phase 3 Clinical Trial in Mild Alzheimer Disease PatientsWednesday 10:15-11:45 |

I-09 Floriane LignetComputational Model of In Vitro Breast Cancer Cells Spheroid-FormationWednesday 10:15-11:45 |

I-10 Lars LindbomAddressing variability and uncertainty in pooled pre-clinical data improved the quality of compound selection of a gamma secretase modulator in Alzheimer’s DiseaseWednesday 10:15-11:45 |

I-11 Rocio LledoDose escalation studies for mAb: prior distributions selection and software comparisonWednesday 10:15-11:45 |

I-13 Gaohua LuApplication of the Simcyp PBPK/PD model to Simulate PK and PD of Nifedipine in Japanese PopulationsWednesday 10:15-11:45 |

I-14 James LuRefining the mechanism of CETP mediated lipid transfer in a stochastic model of lipoprotein metabolism and kinetics (LMK model)Wednesday 10:15-11:45 |

I-15 Peiming MaOrganization of Target-Mediated Disposition (TMD) Models including Michaelis-Menten (MM), rapid-binding (RB), and quasi-steady-state (Qss) modelsWednesday 10:15-11:45 |

I-16 Arianna Madrid AispuroA Systematic Approach to PKPD Model Development to describe Sleep Effects of Compounds with Different Mechanisms of Action Using Semi-Mechanistic Markov Chain ModelsWednesday 10:15-11:45 |

I-17 Victor Mangas-SanjuanThree Compartment Model To Describe Atipical Permeability Profiles In CACO-2 CellsWednesday 10:15-11:45 |

I-18 Mathilde MarchandHow to support a definitive bioequivalence study design using modeling and simulationWednesday 10:15-11:45 |

I-19 John MaringwaModel-based meta-analysis of summary clinical outcome data in idiopathic pulmonary fibrosis (IPF)Wednesday 10:15-11:45 |

I-20 Eleonora MarosticaSecond order Markov modelling of HAMD responses in depression trialsWednesday 10:15-11:45 |

I-21 Amelie MarsotThiopental and esomeprazole in critically ill patients: Drug interaction.Wednesday 10:15-11:45 |

I-22 Silvia IllamolaPopulation pharmacokinetics of amikacin in newbornsWednesday 10:15-11:45 |

I-23 Maria Matoses OsborneDevelopment of a PBPK model for the anticancer drug Vivia009 and its main metabolite administered as a new delivery system in the Rat Wednesday 10:15-11:45 |

I-24 Veronese MattiaOptimal Experimental Design for receptor drug development with PET studiesWednesday 10:15-11:45 |

I-25 Christophe MeilleModified model of drug induced thrombocytopenia efficiently projects safe starting dose in human from preclinical dataWednesday 10:15-11:45 |

I-26 Sven MensingEvaluation of the long-term decline of platelets following Navitoclax (ABT-263) administration in Cancer Patients with a semi-physiological pharmacodynamic model Wednesday 10:15-11:45 |

I-27 François MercierA discussion on two approaches for indirect treatment comparisons based on public-domain metadata: The case of side-effects incidenceWednesday 10:15-11:45 |

I-28 Enrica MezzalanaA Target-Mediated Drug Disposition model to quantify the relationship between Anti-CD3 monoclonal antibody and CD3/TCR receptors in Patients with autoimmune diseases.Wednesday 10:15-11:45 |

I-29 Jonathan MochelUsing nonlinear mixed effects modeling to characterize the pharmacokinetics and pharmacodynamics of benazepril in dogs. Wednesday 10:15-11:45 |

I-30 Samer MouksassiEquivalence of locally acting drugs based on pharmacodynamic data: development of a novel 1 step method and use of trial simulations to assess sources of variability and power definitive studiesWednesday 10:15-11:45 |

I-31 Ricardo Nalda-MolinaStochastic Simulations Assist to Improve a Poorly Designed Clinical Study for the CSF Pharmacokinetics of DoripenemWednesday 10:15-11:45 |

I-32 Carmen NavarroComputer simulations of bioequivalence trials: drugs with sequential metabolismWednesday 10:15-11:45 |

I-33 Michael NeelyNon-Parametric Bayesian Fitting: A Novel Approach to Population Pharmacokinetic ModelingWednesday 10:15-11:45 |

I-34 Thu Thuy NguyenModelling the impact of fecal ciprofloxacin concentrations on fecal counts of resistant Enterobacteriaceae in piglets treated with ciprofloxacin: towards new means to control the spread of resistance? Wednesday 10:15-11:45 |

I-35 Ronald NiebeckerModelling of Anti-Drug Antibodies Directed Against a Monoclonal AntibodyWednesday 10:15-11:45 |

I-36 Christoph NiederaltThe use of physiologically-based pharmacokinetic modeling in the design of pH-dependent target binding antibodiesWednesday 10:15-11:45 |

I-37 Elisabet NielsenTarget Attainment Analysis to Evaluate Dosing Regimens of an Oral β-Lactam AntibioicWednesday 10:15-11:45 |

I-38 Valerie NockComparison of three PK/PD models for glycated haemoglobin in diabetes type 2 patients treated with lixisenatideWednesday 10:15-11:45 |

I-39 Yookhwan NohBioequivalence evaluation using population modeling methodWednesday 10:15-11:45 |

I-40 Joakim NybergThe robustness of global optimal designsWednesday 10:15-11:45 |

I-41 Kayode OgungbenroA semi-mechanistic gastric emptying model for double peaks in pharmacokinetics using LDOPA dataWednesday 10:15-11:45 |

I-42 Katie OwensThe Pharmacokinetic Profile of Intravenous Paracetamol in Adult Patients Undergoing Major Surgery: A Population AnalysisWednesday 10:15-11:45 |

I-43 Sung Min ParkPopulation pharmacokinetics of S-amlodipine in healthy Korean male subjectsWednesday 10:15-11:45 |

I-45 Zinnia Parra-GuillenTumour Growth Modelling In ImmunotherapyWednesday 10:15-11:45 |

I-46 Mélanie PastorModeling of the effect of G-CSF in limiting the neutropenic toxicity of carboplatinWednesday 10:15-11:45 |

I-47 Pavan VajjahPrediction of serum and cerebrospinal fluid concentrations of carbamazepine: An application of parameter estimation and the permeability limited 4-compartment brain model in Simcyp®Wednesday 10:15-11:45 |

I-48 Kirill PeskovMechanistic modeling approach relating human gut microbial community to physiologically-relevant biomarkersWednesday 10:15-11:45 |

I-49 Klas PeterssonSimultaneous modeling of prolactin data following administration of seven D2–receptor antagonists in rats; Model-based in vitro – rat – human scalingWednesday 10:15-11:45 |

I-50 Chiara PianaNon-adherence to antiretroviral combination therapy in HIV-infected childrenWednesday 10:15-11:45 |

I-51 Sabine PilariMathematical Model of Homeostasis of Endogenous Hormones Following Hormone Replacement TherapyWednesday 10:15-11:45 |

I-52 Venkatesh Pilla ReddyTranslational PKPD modeling in schizophrenia: linking receptor occupancy of antipsychotics to efficacy and safetyWednesday 10:15-11:45 |

I-53 Elodie PlanBayesian Joint Modeling of Bone Mineral Density and Repeated Time-To-Fracture Event for Multiscale Bone Systems Model Extension Wednesday 10:15-11:45 |

I-54 Bart PloegerInvestigation of a Data Transformation Procedure to Improve Identifiability of Efficacy and Potency: Application to Continuous Elevated Plus-Maze Data in RatsWednesday 10:15-11:45 |

I-55 Arnaud QuelinHow Anti-cancer Targeted Therapies Used in Combination Interact? Analysis with a Semi-mechanistic Model of Minimal Signalling NetworksWednesday 10:15-11:45 |

I-56 Christian Hove ClaussenPharmacokinetics of concentrated insulin mixtures: a biosimulation approachWednesday 10:15-11:45 |

I-57 Dinko RekicExternal validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1 infected patients Wednesday 10:15-11:45 |

I-58 Sylvie RetoutPrediction of occurrence of thrombocytopenia to select Phase 1b dose and dosing regimen for a selective inhibitor of p53-MDM2 in patients with solid tumorsWednesday 10:15-11:45 |

I-59 Benjamin RibbaA model for low-grade glioma tumor growth and response to chemotherapy and radiotherapyWednesday 10:15-11:45 |

I-60 Nikita RodichenkoMultimodal Physiologically-Based Modelling and Analysis of Kinetics of Drug-Delivery with Modular Nanotransporters (MNT)Wednesday 10:15-11:45 |

I-61 Rikke Meldgaard RøgeIntegrated model of glucose homeostasis including the effect of exogenous insulin Wednesday 10:15-11:45 |

I-62 Hyerang RohQuantitative assessment of drug response in male patients with severe nocturia receiving a combined medication of solifenacin and tamsulosinWednesday 10:15-11:45 |

I-63 Rachel RosePrediction of the Hypnotic Effects of Zolpidem by Extrapolation of a Mechanism-Based PKPD Model Developed for Triazolam in Healthy Volunteers.Wednesday 10:15-11:45 |

I-64 Roel StraetemansPharmacokinetic/Pharmacodynamic Simulations Of The vWF Targeting Nanobody® ALX-0081 In Pediatric Patients With TTPWednesday 10:15-11:45 |

I-65 Amit RoyCharacterization of the Occurrence, Severity, and Duration of Immune-Related Adverse Events (irAEs) in Advanced Melanoma Patients Treated with IpilimumabWednesday 10:15-11:45 |

I-66 Hauke RuehsIntegrated PK/PD model for oxaliplatin in different human matricesWednesday 10:15-11:45 |

I-67 Alberto RussuA new, second-order indirect model of depression time courseWednesday 10:15-11:45 |

I-68 Vargo RyanComparator based dose-response model prediction of clinical irrelevance following near miss bioequivalence results for CmaxWednesday 10:15-11:45 |

I-69 Yu-Yuan ChiuDose-Response Model of Lurasidone Treatment in SchizophreniaWednesday 10:15-11:45 |